Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.
William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."
Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.
Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06, “Stromal tumor-infiltrating lymphocytes: In the Alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit.”
William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1 and SOFT trials.
Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.
